UNH

In the past six months (April-October 2026), UNH's stock experienced fluctuations, rising from $368.38 in April to a 52-week high of $461.62 in July, then declining to $367.08 in September before trading around $376.20 in October. Key influences included Q1 and Q2 2026 earnings releases, with Q2 reporting $112.0 billion in revenue and raising the full-year adjusted earnings outlook. The stock was also impacted by medical cost pressures, regulatory scrutiny, the high-profile assassination of the company's CEO in December 2024, rising care utilization, and changes in Medicare Advantage star ratings. Analysts generally maintain a 'Buy' rating, though some have lowered price targets due to caution regarding margins and medical costs, with Q3 2026 earnings anticipated in October.